Hong Kong’s Hospital Authority pledges to reduce ethics review process on clinical trials from 6 months to 30 days starting next year

“We will have a performance pledge. We will clear the review within 30 days,” he added.

Lower-risk clinical trials refer to studies that do not involve offering treatment or medication to patients, such as those that review data, according to Wong.

Hong Kong should create new office to run medical research: experts

Wong told the Post that efficiency could be improved with a streamlined process requiring just one application for an ethics review, hoping it could be on par with other developed countries.

He said that currently it could take as many as six months just to process an ethics review. With the new mechanism in place, the procedure could be compressed to 30 days.

But for higher-risk clinical trials that involved treating patients, the process of an ethics review could still take as many as 60 working days, Wong said.

He also said the new arrangement was expected to take effect in the first quarter of 2024.

In October, Chief Executive John Lee Ka-chiu revealed in the latest policy address that developing Hong Kong into a health and medical innovation hub would be a major initiative of the authorities.

A Cluster Clinical Research Support Office, to be set up by the authority, will provide advice and support services for frontline staff taking part in clinical research, as well as expedite the process of ethics review on clinical research.

Hong Kong scientists get rare US approval for trials of constipation drug

Professor Ivan Hung Fan-ngai, a top infectious diseases expert at the University of Hong Kong, said that the new move could make the city more competitive in conducting clinical trials.

“[The new arrangement] will be more attractive to multi-centre trials,” Hung said.

He said some major pharmaceutical trials shunned Hong Kong over the lengthy ethics review process.

The Our Hong Kong Foundation report said that the number of clinical trials conducted in the city had declined by 22 per cent between 2015 and 2021, lagging behind an average of 48 per cent increase in major economies and the exponential growth of 285 per cent in mainland China.

Sabrina Chan So-kuen, senior executive director of the Hong Kong Association of the Pharmaceutical Industry, welcomed the latest move and said it is a “big improvement” for the authority.

But she also wondered whether the benchmark of 30 days could be applied to all clinical trials, without differentiating lower- or higher-risk ones.

More cross-border collaboration to boost Hong Kong’s medical innovation hub plans

She said that in many countries, including Singapore and Australia, an ethics review for all types of clinical trials took around 30 days, and hoped that Hong Kong could take the same step.

Highlighting the importance of speed in conducting clinical trials, Chan said that shortening the processing time could raise Hong Kong’s competitiveness in seeking research and the number of companies conducting trials in the city.

“We need to compete with the others in the global environment, and speed is one of the criteria,” she said.